Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):251-9. doi: 10.1586/erp.13.12.

Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer.

Author information

  • 1Hind T Hatoum & Company, 155 N Harbor Drive, 1912, Chicago, IL 60601, USA. hthatoum@sbcglobal.net

Abstract

Androgen deprivation therapy (ADT) is used as first-line therapy for locally advanced or metastatic prostate cancer aiming to reduce testosterone to castrate levels. The authors present an overview of the existing cost-effectiveness studies of ADT in prostate cancer. Cost-effectiveness of ADT was reviewed using a systematic search of the peer-reviewed literature, as well as research abstracts presented at various scientific and industry meetings. Most cost-effectiveness analyses of ADT reported results within the accepted societal threshold of US$50,000 cost/quality-adjusted life year needed to adopt new technology.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Write to the Help Desk